Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 6
2005 3
2006 4
2007 7
2008 7
2009 8
2010 4
2011 5
2012 8
2013 6
2014 13
2015 5
2016 5
2017 10
2018 11
2019 10
2020 18
2021 21
2022 20
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Subconjunctival dirofilariasis.
Wylęgała A, Wróblewska-Czajka E, Wylęgała E. Wylęgała A, et al. Among authors: wylegala e. Am J Ophthalmol. 2022 Jan;233:e1. doi: 10.1016/j.ajo.2021.10.016. Epub 2021 Oct 22. Am J Ophthalmol. 2022. PMID: 34695396 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Intraoperative OCT microscopy in 3D.
Wylęgała A, Sendecki A, Wylęgała E. Wylęgała A, et al. Among authors: wylegala e. Expert Rev Med Devices. 2021 Mar;18(3):221-224. doi: 10.1080/17434440.2021.1898374. Epub 2021 Mar 19. Expert Rev Med Devices. 2021. PMID: 33651642 No abstract available.
Visual Acuity Examination Methodology in Keratoconus.
Nandzik M, Wylęgała E, Wylęgała A, Szkodny D, Roszkowska AM, Wróblewska-Czajka E. Nandzik M, et al. Among authors: wylegala e. J Clin Med. 2023 Dec 11;12(24):7620. doi: 10.3390/jcm12247620. J Clin Med. 2023. PMID: 38137688 Free PMC article. Review.
Optical coherence angiography: A review.
Wylęgała A, Teper S, Dobrowolski D, Wylęgała E. Wylęgała A, et al. Among authors: wylegala e. Medicine (Baltimore). 2016 Oct;95(41):e4907. doi: 10.1097/MD.0000000000004907. Medicine (Baltimore). 2016. PMID: 27741104 Free PMC article. Review.
[Meibomian gland dysfunction--review].
Nowińska A, Wylegała E, Tarnawska D, Janiszewska D, Dobrowolskia D. Nowińska A, et al. Among authors: wylegala e. Klin Oczna. 2012;114(2):147-52. Klin Oczna. 2012. PMID: 23346806 Review. Polish.
186 results